ARA-290, also called cibinetide, is an investigational peptide derived from erythropoietin research and designed to activate tissue-protective signaling without stimulating red-blood-cell production. Small human trials have studied neuropathy-related outcomes, but it is not an FDA-approved treatment.

ARA-290 at a glance

Why is ARA-290 being studied?

Erythropoietin biology includes more than blood-cell production. Researchers designed ARA-290 to explore tissue-protective and anti-inflammatory signaling while avoiding erythropoietic effects. Online discussions often extend that rationale to nerve pain, nerve damage, inflammation, and recovery, but each proposed use requires its own clinical evidence.

What have human trials found?

A small double-blind pilot trial in 22 people with sarcoidosis and small-fiber-neuropathy symptoms reported improvement in a neuropathy symptom score, while pain and fatigue measures improved similarly in both groups. A later 64-person phase 2b trial reported a change in corneal nerve-fiber area at one studied level and exploratory relationships with other measures; pain findings were less definitive. A phase 2 study in type 2 diabetes also reported metabolic and neuropathy-related signals. These studies justify further research, not broad clinical conclusions.

Surrogate endpoints versus patient outcomes

Nerve-fiber imaging and laboratory measures can provide evidence of biological activity, but they are not automatically equivalent to durable relief, restored function, prevention of disability, or long-term safety. Small samples, short follow-up, multiple endpoints, and dose-group comparisons also increase uncertainty.

Safety and product uncertainties

The published trials provide limited short-term information in selected participants. They cannot resolve rare adverse events, long-term immune effects, interactions, use in pregnancy, use across unrelated neurologic disorders, or risks in people with complex illness. Products sold outside trials may not match the studied molecule in identity, purity, formulation, storage, or sterility.

What people report online

Community-reported—not proof: accounts discuss burning pain, tingling, numbness, fatigue, glucose control, and combinations with other compounds. Underlying diagnoses and co-interventions vary widely; without product verification and controlled comparison, improvement or harm cannot be confidently attributed to ARA-290.

Bottom line

ARA-290 has more human research than many retail “research peptides,” but the evidence remains early, condition-specific, and insufficient for presenting it as an established neuropathy treatment. A useful summary is “investigational with preliminary human signals,” not “proven nerve repair.”

Primary sources

• Randomized pilot study in sarcoidosis-associated small-fiber neuropathy
• Phase 2b randomized cibinetide trial
• Phase 2 ARA-290 study in type 2 diabetes and neuropathy
• ClinicalTrials.gov study record

Educational evidence review only. Nerve pain or new neurologic symptoms warrant professional evaluation. No dosing, injection, or treatment protocol is provided.